CGRP monoclonal antibody LY2951742 for the prevention of migraine: a phase 2, randomized, double-blind, placebo-controlled study

被引：0
|
作者：
Goadsby, P. [1 ,2 ,3 ]
Dodick, D. [4 ]
Spierings, E. [5 ,6 ,7 ]
Scherer, J. [8 ]
Sweeney, S. [9 ]
Grayzel, D. [9 ]
机构：
[1] Kings Coll London, NIHR Wellcome Trust Clin Res Facil KCL, London WC2R 2LS, England
[2] Kings Coll London, Dept Neurol UCSF, London WC2R 2LS, England
[3] Univ Calif San Francisco, London, England
[4] Mayo Clin, Dept Neurol, Phoenix, AZ USA
[5] Harvard Univ, Brigham & Womens Hosp, Dept Neurol BWH, Sch Med, Boston, MA 02115 USA
[6] Harvard Univ, Brigham & Womens Hosp, Headache & Face Pain Program, Sch Med, Boston, MA 02115 USA
[7] Tufts Sch Dent Med, Boston, MA USA
[8] Eli Lilly & Co, Indianapolis, IN 46285 USA
[9] Arteaus Therapeut, Cambridge, MA USA
来源：
JOURNAL OF HEADACHE AND PAIN | 2014年 / 15卷
关键词：
Placebo; Migraine; Calcitonin; Injection Site; Secondary Endpoint;
D O I：
10.1186/1129-2377-15-S1-G10
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EHMTI-0178
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Prevention of menstrual attacks of migraine - A double-blind placebo-controlled crossover study
    MacGregor, E. A.
    Frith, A.
    Ellis, J.
    Aspinall, L.
    Hackshaw, A.
    NEUROLOGY, 2006, 67 (12) : 2159 - 2163
  • [32] NAPROXEN IN THE PREVENTION OF MIGRAINE ATTACKS - DOUBLE-BLIND PLACEBO-CONTROLLED CROSSOVER STUDY
    LINDEGAARD, KF
    OVRELID, L
    SJAASTAD, O
    HEADACHE, 1980, 20 (02): : 96 - 98
  • [33] A Randomized, Double-Blind, Placebo-Controlled, Proof of-Concept Study of LY2300559 for Migraine Prophylaxis in Patients with Migraine
    Robertson-Plouch, C.
    Silberstein, S.
    Birch, C.
    Ardayfio, P.
    Brittain, C.
    CEPHALALGIA, 2013, 33 (11) : 969 - 969
  • [34] GLANCE Results of a phase 2, randomized, double-blind, placebo-controlled study
    Goodman, A. D.
    Rossman, H.
    Bar-Or, A.
    Miller, A.
    Miller, D. H.
    Schmierer, K.
    Lublin, F.
    Khan, O.
    Bormann, N. M.
    Yang, M.
    Panzara, M. A.
    Sandrock, A. W.
    NEUROLOGY, 2009, 72 (09) : 806 - 812
  • [35] Haloperidol in the acute treatment of migraine: A randomized, double-blind, placebo-controlled study
    Honkaniemi, J
    Liimatainen, S
    Rainesalo, S
    Sulavuori, S
    HEADACHE, 2006, 46 (05): : 781 - 787
  • [36] Galcanezumab in chronic migraine The randomized, double-blind, placebo-controlled REGAIN study
    Detke, Holland C.
    Goadsby, Peter J.
    Wang, Shufang
    Friedman, Deborah I.
    Selzler, Katherine J.
    Aurora, Sheena K.
    NEUROLOGY, 2018, 91 (24) : E2211 - E2221
  • [37] PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ERENUMAB (AMG 334) IN CHRONIC MIGRAINE PREVENTION
    Tepper, S.
    Widnell, K.
    Dolezil, D.
    Ashina, M.
    Reuter, U.
    Brandes, J. Lewis
    Silberstein, S.
    Winner, P.
    Leonardi, D.
    Mikol, D.
    CEPHALALGIA, 2016, 36 : 44 - 45
  • [38] A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Chronic Migraine Prevention
    Tepper, S. J.
    Dolezil, D.
    Ashina, M.
    Reuter, U.
    Brandes, J. L.
    Silberstein, S. D.
    Winner, P.
    Leonardi, D. K.
    Mikol, D. D.
    HEADACHE, 2017, 57 : 130 - 130
  • [39] Results of a randomized, double-blind, placebo-controlled, phase 2 study to evaluate the efficacy and safety of AMG 334 for the prevention of episodic migraine
    Lenz, R.
    Silberstein, S.
    Dodick, D.
    Reuter, U.
    Ashina, M.
    Saper, J.
    Cady, R.
    Chon, Y.
    Dietrich, J.
    Sun, H.
    CEPHALALGIA, 2015, 35 : 5 - 5
  • [40] Evaluating the Efficacy and Safety of Erenumab (AMG 334) In Chronic Migraine Prevention in a Phase 2 Randomized, Double-Blind, Placebo-Controlled Study
    Tepper, Stewart
    Widnell, Katherine
    Dolezil, David
    Ashina, Messoud
    Reuter, Uwe
    Brandes, Jan Lewis
    Silberstein, Stephen
    Winner, Paul
    Leonardi, Dean
    Mikol, Dan
    NEUROLOGY, 2017, 88
12345